Similarly, in a recent Phase 1b/2 study evaluating the combination of venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide (ViPOR) in relapsed or refractory DLBCL, higher response rates have been observed in non‐GCB cases as well as in high‐grade B‐cell lymphoma with MYC and BCL2 rearrangement.43 This evidence concerns the gene BCL2 and B-cell non-Hodgkin lymphoma.